«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2025年03期

页码:

395-400

栏目:

论著

出版日期:

2025-06-25

文章信息/Info

Title:

Significance of circulating tumor DNA in predicting postoperative recurrence risk of non-small cell lung cancer

作者:

乔鲜丽¹; 田向阳¹; 周文雅¹; 秦泽敏¹; 郭姗姗²; 于俊岩¹

046000 长治,长治医学院附属和平医院肿瘤科¹
100088 北京,中国人民解放军火箭军特色医学中心全科医学²

Author(s):

Qiao Xianli¹;  Tian Xiangyang¹;  Zhou Wenya¹;  Qin Zemin¹;  Guo Shanshan²;  Yu Junyan¹.

¹Department of Oncology, Changzhi Medical College Affiliated Peace Hospital, Changzhi 046000, China; ²Department of General Practice, PLA Rocket Army Characteristic Medical Center, Beijing 100088, China

关键词:

非小细胞肺癌;  循环肿瘤DNA;  微小残留病灶;  复发;  根治性切除

Keywords:

Non-small cell lung cancer;  Circulating tumor DNA;  Minimal residual disease;  Recurrence;  Radical resection

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2025.03.010

摘要:

目的 分析循环肿瘤DNA(circulating tumor DNA, ctDNA)对非小细胞肺癌(non-small cell lung cancer, NSCLC)根治性手术后早期复发风险的预测意义。方法 选择2020年2月至2023年12月我院收治的81例NSCLC患者,完成根治性切除术,收集肿瘤标本,采集血液样本,采用基于液体活检的循环单分子扩增和重测序技术(circulating single-molecule amplification and resequencing technology, cSMART)进行ctDNA分析,记录无复发生存期(relapse-free survival,RFS)和总生存期(overall survival, OS),分析ctDNA与RFS、OS关系。结果 81例平均基因突变(1.73±0.65)个,50例(61.73%)术前ctDNA阳性,76例中33例(43.42%)术后至少1个检测点ctDNA阳性。50例术前ctDNA阳性者中26例术后ctDNA阳性。中位随访44.0个月,81例NSCLC患者生存55例(67.90%),其中复发者37例(45.68%),死亡者26例(32.10%)。术前ctDNA阳性者中位RFS期19.0个月(log rank=12.531,P<0.001)和OS期34.89个月(log rank=11.028,P=0.001)短于ctDNA阴性者RFS期42.0个月、OS期46.65个月。术后33例ctDNA阳性者中复发21例(63.64%),死亡15例(45.45%)。术后ctDNA阳性者中位RFS期25.79个月(log rank=10.796,P=0.001)和OS期34.21个月(log rank=7.384,P=0.007)短于术后ctDNA阴性者RFS期39.0个月、OS期43.15个月。43例术后ctDNA阴性者影像学结果显示病灶完全切除,其中21例术前ctDNA阳性,ctDNA转阴者中位RFS期38.05个月(log rank=5.139,P=0.023)长于ctDNA未转阴者25.92个月。术前ctDNA阴性31例中7例(22.58%)术后ctDNA转阳。33例术后ctDNA阳性者中21例术后ctDNA阳性比影像学或临床症状结果平均早(11.12±5.21)个月,其中17例术后2周内ctDNA呈阳性。多因素分析显示,临床分期和术前ctDNA状态对RFS和OS具有统计学意义(P<0.05)。高分期(Ⅲ期)较低分期(Ⅰ/Ⅱ期)NSCLC复发或死亡风险分别是3.082倍或3.577倍。术前ctDNA阳性较ctDNA阴性NSCLC复发或死亡风险增加3.889倍或3.139倍。术后ctDNA阳性是影响RFS的因素(P<0.05),复发风险增加3.333倍。结论 晚期和术前ctDNA阳性是经根治性切除NSCLC患者RFS和OS的影响因素。术后检测ctDNA有助于早期发现复发具有意义。

Abstract:

Objective To analyze the predictive significance of circulating tumor DNA(ctDNA)in the risk of early recurrence of non-small cell lung cancer(NSCLC)after radical surgery. Methods All of 81 patients with NSCLC admitted to our hospital from February 2020 to December 2023 were selected. Radical resection was completed, tumor specimens and blood samples were collected. ctDNA analysis was performed using circulating single-molecule amplification and resequencing technology(cSMART)based on liquid biopsy. Relapse-free survival(RFS)and overall survival(OS)were recorded, and the relationship between ctDNA and RFS and OS was analyzed. Results 81 cases had an average of(1.73±0.65)gene mutations, 50 cases(61.73%)were positive ctDNA before surgery, and 33 of 76 cases(43.42%)were positive ctDNA at least one point after surgery. Among the 50 patients with positive ctDNA before surgery, 26 patients had positive ctDNA after surgery. During a median follow-up of 44.0 months, Among the 81 NSCLC patients, 55 survived(67.90%), 37 cases(45.68%)relapsed and 26 cases(32.10%)died. The median RFS stage was 19.0 months(log rank=12.531, P<0.001)and OS stage was 34.89 months(log rank=11.028, P=0.001)in ctDNA-positive patients before surgery, and the median RFS stage was 42.0 months and OS stage was 46.65 months in ctDNA-negative patients. Among the 33 ctDNA positive patients, 21 casses(63.64%)relapsed and 15 cases(45.45%)died. The median RFS duration of 25.79 months(log rank=10.796, P=0.001)and OS duration of 34.21 months(log rank=7.384, P=0.007)in ctDNA-positive patients were shorter than those in ctDNA-negative patients(39.0 months of RFS and 43.15 months of OS). The imaging results of 43 patients with negative ctDNA after surgery showed complete resection of the lesions, and 21 cases of them were positive ctDNA before surgery. The median RFS duration of those with negative ctDNA was 38.05 months(log rank=5.139, P=0.023), which was longer than that of those without negative ctDNA. 31 patients with negative ctDNA before surgery, 7 cases(22.58%)had positive ctDNA conversion after surgery. Among the 33 ctDNA positive cases, 21 cases had positive ctDNA after surgery(11.12±5.21)months earlier than the average results of imaging or clinical symptoms, and 17 cases had positive ctDNA within 2 weeks after surgery. Multifactor analysis showed that clinical stage and preoperative ctDNA status had statistical significance for RFS and OS(P<0.05). The risk of recurrence or death from high stage(stage Ⅲ)and low stage(stage Ⅰ/Ⅱ)NSCLC was 3.082 times or 3.577 times, respectively. Preoperative ctDNA-positive NSCLC had 3.889 times or 3.139 times increased risk of recurrence or death compared with ctDNA-negative NSCLC. Positive ctDNA was a factor affecting RFS after operation(P<0.05), and the risk of recurrence was increased by 3.333 times. Conclusion Advanced stage and preoperative ctDNA positive are the factors affecting RFS and OS in patients with radical resection of NSCLC. The detection of ctDNA after surgery can help to detect recurrence in time.

参考文献/References:

1 Kratzer TB, Bandi P, Freedman ND, et al. Lung cancer statistics, 2023[J]. Cancer, 2024, 130(8): 1330-1348.
2 Bitenc M, Cufer T, Kern I, et al. Real-life long-term outcomes of upfront surgery in patients with resectable stage Ⅰ-ⅢA non-small cell lung cancer[J]. Radiol Oncol, 2022, 56(3): 346-354.
3 Zheng X, Li C, Ai J, et al. No prognostic impact of staging bone scan in patients with stage ⅠA non-small cell lung cancer[J]. Ann Nucl Med, 2024, 38(7): 534-543.
4 晨正宇, 周 薇, 熊 婧, 等. 基于ctDNA的分子残留病灶检测对非小细胞肺癌根治术后生存的预测效能[J]. 局解手术学杂志, 2023, 32(5): 416-420.
5 Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling[J]. Cancer Discov, 2017, 7(12): 1394-1403.
6 Wu T, Fan R, Bai J, et al. The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis[J]. J Hematol Oncol, 2023, 16(1): 1.
7 王 磊, 刘 先, 吴清辉, 等. 循环肿瘤DNA与EGFR、KRAS、NRAS突变型可切除非小细胞肺癌的病理关系[J]. 局解手术学杂志, 2025, 34(2): 154-158.
8 叶博文, 陈毅来, 张晏玮, 等. 循环肿瘤DNA液态活检检测微小残留病在实体肿瘤诊疗中的研究进展[J]. 同济大学学报(医学版), 2024, 45(2): 290-296.
9 Wang Z, Cheng G, Han X, et al. Application of single-molecule amplification and resequencing technology for broad surveillance of plasma mutations in patients with advanced lung adenocarcinoma[J]. J Mol Diagn, 2017, 19(1): 169-181.
10 李芳颖, 鄂 颖, 井明晰, 等. 基于cSMART技术检测ctDNA驱动基因突变指导非小细胞肺癌精准治疗的疗效研究[J]. 中国癌症防治杂志, 2019, 11(2): 110-115.
11 Heo J, Kim YN, Shin S, et al. Serial circulating tumor DNA analysis with a tumor-naïve next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer[J]. Cancer Res, 2024, 84(3): 468-478.
12 Wehrle CJ, Hong H, Kamath S, et al. Tumor mutational burden from circulating tumor DNA predicts recurrence of hepatocellular carcinoma after resection: An emerging biomarker for surveillance[J]. Ann Surg, 2024, 280(3): 504-513.
13 徐海青, 宋烈晶, 丁重阳. 弥漫大B细胞淋巴瘤¹⁸F-FDG PET/CT代谢参数和循环肿瘤DNA突变丰度:相关性和生存分析[J]. 中国实验血液学杂志, 2023, 31(6): 1690-1700.
14 Gale D, Heider K, Ruiz-Valdepenas A, et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer[J]. Ann Oncol, 2022, 33(5): 500-510.
15 Chidharla A, Rapoport E, Agarwal K, et al. Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: A systematic review and Meta-analysis[J]. Int J Mol Sci, 2023, 24(12): 10230.
16 徐福东,车南颖. 基于血浆cfDNA片段特征的癌症诊断技术研究进展[J]. 诊断病理学杂志, 2024, 31(3): 248-251.
17 Xia L, Mei J, Kang R, et al. Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: A prospective multicenter cohort study(LUNGCA-1)[J]. Clin Cancer Res, 2022, 28(15): 3308-3317.
18 Ohara S, Suda K, Sakai K, et al. Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study[J]. Transl Lung Cancer Res, 2020, 9(5): 1915-1923.
19 王 伟,谢宵靓,姜国忠, 等. 晚期非小细胞肺癌患者外周血中多个驱动基因和TP53基因检测[J]. 郑州大学学报(医学版), 2020, 55(2): 187-191.
20 Li Y, Jiang G, Wu W, et al. Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease[J]. EBioMedicine, 2023, 91: 104553.
21 Yue D, Liu W, Chen C, et al. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients[J]. Transl Lung Cancer Res, 2022, 11(2): 263-276.
22 张国英, 赵 鸽, 苗金红. PLR、微卫星状态及ctDNA对肢端恶性黑色素瘤术后复发的评估作用[J]. 实用癌症杂志, 2023, 38(11): 1907-1910.
23 曹俊英,张应华,李 婷. 循环肿瘤DNA检测对胃癌患者疾病进展和肿瘤复发的预测价值[J]. 南昌大学学报(医学版), 2023, 63(3): 29-33, 43.
24 何焯坤,李 宁,耿 庆. 《早期可切除非小细胞肺癌的新辅助治疗和辅助治疗:国际肺癌研究协会的共识建议》解读[J]. 中国胸心血管外科临床杂志, 2025, 32(3): 291-299.
25 孙伟臻,周宇桁,林耀彬, 等. ALK融合阳性非小细胞肺癌新辅助靶向治疗的进展[J]. 中国肺癌杂志, 2024, 27(11): 849-854.
26 张哲铭, 李文雅. 新辅助免疫治疗对非小细胞肺癌手术诊疗策略的影响[J]. 现代肿瘤医学, 2024, 32(23): 4548-4554.
27 Spicer JD, Garassino MC, Wakelee H, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer(KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2024, 404(10459): 1240-12.
28 Abbosh C, Hodgson D, Doherty GJ, et al. Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer[J]. Trends Cancer, 2024, 10(7): 643-654.
29 Li HJ, Zhang JT, Dong S, et al. CtDNA based molecular residual disease outcompetes carcinoembryonic antigen in predicting postoperative recurrence of non-small cell lung cancer[J]. J Thorac Dis, 2024, 16(1): 423-429.
30 Moding EJ, Liu Y, Nabet BY, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer[J]. Nat Cancer, 2020, 1(2): 176-183.

备注/Memo

备注/Memo:

基金项目: 2022年度军队后勤科研面上项目(20221107)
通信作者: 于俊岩, Email: qiaoqiao202401@126.com

常用功能

更新日期/Last Update: 2025-06-25